[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-syndrome":762},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,173,0,25,[9,52,86,99,161,186,220,249,275,322,347,371,389,421,446,475,501,532,552,578,609,637,693,713,737],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100054144",false,"NCT07313787","Effects of Meal Macronutrients on Postprandial Lipids","Prospective Cross-Over Study of the Effects of Meal Macronutrients on Postprandial Lipids","* INCLUSION CRITERIA:\n\nCommon inclusion criteria (all groups):\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age \\>= 18 years\n2. Average alcohol intake in the past 6 months \\\u003C 3 drinks (approximately 30g) per day (male) or \\\u003C 2 drinks (approximately 20 g) per day (female)\n\nHealthy control specific inclusion criteria:\n\n1. In good general health with no known active medical conditions as evidenced by medical history\n2. Fasting glucose \\\u003C100 mg\u002FdL\n3. HbA1c \\\u003C5.7%\n4. Fasting triglycerides \\\u003C150 mg\u002FdL\n5. ALT and AST within normal limits\n6. BMI \\>=18.5 to \\\u003C25 kg\u002Fm\\^2 (or \\\u003C23 kg\u002Fm\\^2 in participants of Asian descent)\n7. Not taking any medications or supplements that, in the opinion of the investigator, would interfere with interpretation of study data.\n\nMetabolic syndrome specific inclusion criteria\n\n1\\. Obesity defined as either\n\n1. BMI \\>30 kg\u002Fm\\^2 (or \\>=27 kg\u002Fm\\^2 in participants of Asian descent), OR\n2. Elevated waist circumference as defined below:\n\n   * Country\u002FEthnic group - Europid, Sub-Saharan African, Eastern Mediterranean and Middle East (Arab):\n\n     --Sex: Male - Waist circumference: \\>=94cm\n\n     --Sex: Female - Waist circumference: \\>=80cm\n   * Country\u002FEthnic group - South Asian, Chinese, Japanese, Ethnic South and Central American:\n\n     * Sex: Male - Waist circumference: \\>=90cm\n     * Sex: Female - Waist circumference: \\>=80cm\n\n       2\\. Elevated triglycerides defined as EITHER\n\n       2a. Fasting triglycerides \\>= 150 mg\u002FdL at screening, OR\n\n       2b. Specific treatment for hypertriglyceridemia\n\n       3\\. Low HDL cholesterol, defined as EITHER\n\n       3a. HDL \\\u003C40 mg\u002FdL (males) or \\\u003C50 mg\u002FdL (females) at screening, OR\n\n       3b. Specific treatment for low HDL\n\n       4\\. Elevated blood pressure defined as EITHER\n\n       4a. Systolic BP \\>= 130 at screening, OR\n\n       4b. Diastolic BP \\>= 85 mm Hg at screening, OR\n\n       4c. Treatment of previously diagnosed hypertension\n\n       5\\. Elevated glucose defined as EITHER\n\n       5a. HbA1c \\>= 5.7% (at screening), OR\n\n       5b. Fasting serum glucose \\>= 100 mg\u002FdL (at screening), OR\n\n       5c. 2-hour post-load glucose levels \\>= 140 mg\u002FdL (by history), OR\n\n       5d. Prior diagnosis of type 2 diabetes\n\n   Lipodystrophy-specific inclusion criteria:\n   1. Clinical diagnosis of generalized or partial lipodystrophy based on reduction in adipose tissue outside the normal range in some or all adipose depots (including, at aminimum, the gluteofemoral depot).\n   2. Insulin resistance as defined by fasting insulin \\>22.5 or high exogenous insulin requirement (\\> 2 units per kg per day or \\> 200 units total per day) at screening.\n\n   Nephrotic syndrome specific inclusion criteria\n   1. History of biopsy proven non-diabetic glomerular disease (any histology)\n   2. Nephrotic range proteinuria defined by ANY of the following:\n\n   2a. Protein\u002Fcreatinine ratio uPCR \\>= 3.5 g\u002Fg at screening, OR\n\n   2b. 24 hour protein excretion \\>= 3.5 gr\u002F24hr) at screening, OR\n\n   2c. History of nephrotic range proteinuria (as defined above) within the past 5 years but in complete (defined as proteinuria \\\u003C= 0.3 g\u002Fday or partial remission (defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria \\\u003C 3.5 g\u002Fday) based on 24 hr urine or uPCR at time of screening\n\n   EXCLUSION CRITERIA:\n\n   Common exclusion criteria (all groups):\n\n   An individual who meets any of the following criteria will be excluded from participation in this study:\n   1. Consuming extreme macronutrient diet (e.g., very low-carbohydrate, high fat diets such as ketogenic, paleo or Atkins diets, among others).\n   2. Plans to actively gain or lose weight during the study period (other than changes in water balance as clinically needed in subjects with nephrotic syndrome).\n   3. Change in body weight of \\>5% or \\>3 kg (whichever is larger) in the 3 months prior to screening (by participant report) in participants who do NOT have nephrotic syndrome.\n   4. Body weight \\>450 lbs (upper limit that can be accommodated by DXA scanner).\n   5. Participating in a regular strenuous exercise program (\\> 2h\u002Fweek of vigorous activity) as determined by volunteer report or evidence of vigorous exercising in order to lose weight, change body shape, or to counteract the effects of eating.\n   6. Uncontrolled diabetes, defined as HbA1c \\>9% at screening.\n   7. Lipemia defined as fasting or non-fasting triglycerides of \\>1000 mg\u002FdL at screening.\n   8. Renal dysfunction defined as eGFR \\\u003C50 mL\u002Fmin\u002F1.73 m\\^2 at screening.\n   9. In participants with liver disease, history of decompensated advanced liver disease, defined as direct bilirubin \\> 0.5 g\u002FdL, PT \\> 18 seconds, albumin \\\u003C 3 g\u002FdL, MELD score \\> 12, or history of ascites, encephalopathy, variceal bleeding, spontaneous bacterial\n\n      peritonitis or liver transplant.\n   10. History of hypertriglyceridemia-induced pancreatitis within 3 months prior to screening.\n   11. Positive pregnancy test or breastfeeding at screening.\n   12. Clinically significant abnormalities in thyroid function, blood counts, as assessed by screening labs.\n   13. Acute cardiovascular events within the past 6 months\n   14. Anemia (Hgb \\\u003C10 mg\u002FdL in women or \\\u003C12 mg\u002FdL in men) at screening\n   15. Food allergies or other dietary restrictions that could increase risk associated with test meals or cause the subject to be unwilling to consume test meals (i.e. celiac disease, vegan diets).\n   16. Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.\n   17. Subjects treated with tamoxifen, estrogens, or progestins that have not been stable for \\>4 weeks prior to screening.\n   18. Blood donation in the last 2 weeks or planned blood donation during the study\n   19. Subjects requiring regular transfusions for any reason.\n   20. Subjects with known gastroparesis\n   21. Inability to adhere to Lifestyle Considerations throughout study duration.\n   22. Inability of the subject to understand and the unwillingness to sign a written informed consent document.\n   23. Unwillingness to comply with all study procedures and unavailable for the duration of the study\n   24. Any other condition or medication which, in the opinion of the investigator, increases risk to the subject, prevents the subject from complying with study procedures, prevents the subject from completing the study, or interferes with the interpretation of study results.","ALL","18 Years","120 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nAbnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome.\n\nObjective:\n\nTo learn more about how different types of foods affect fat levels in the blood.\n\nEligibility:\n\nPeople aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal.\n\nParticipants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after.\n\nParticipants will have other tests during their stays:\n\n* A resting metabolic test captures the air they exhale and measures how much energy they use at rest.\n* A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have.\n* A Fibroscan is a special type of ultrasound of the liver.\n* A body surface scan uses lasers to measure the total area of the body.\n* A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body.\n\nParticipants may opt to have a third visit. At this visit, the breakfast will be high in protein....",[27,28,29,30,31,32],"Nephrotic Syndrome","Lipodystrophy","Metabolic Syndrome","Healthy Volunteer","Diabetes","Metabolic Associated Steatotic Liver Disease",[34,35,36,37,38],"postprandial lipids","macronutrient","CARBOHYDRATES","FATS","Proteins","NOT_YET_RECRUITING","2026-07-10",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":21},"2026-07-16",{"date":47,"type":21},"2031-08-01",{"name":49,"class":50},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":53,"slug":4,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":51},"100053768","NCT07697469","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization (ATRIO-CKM)","ATRIO-CKM","Inclusion Criteria:\n\n* Adults aged 18 years or older presenting for cardiovascular evaluation Signed written informed consent Agreement with all protocol requirements\n\nExclusion Criteria:\n\n* Missing key data for ACM or CKM classification Hemodynamically significant valvular heart disease (greater than moderate severity) Mechanical or biological valve prostheses Temporary or permanent cardiac pacing Psychiatric pathology Thyroid pathology (active or untreated) Known cardiomyopathies (hypertrophic, dilated, restrictive, or infiltrative) Refusal to participate or inability to comply with protocol requirements",{"count":60,"type":21},200,"OBSERVATIONAL","Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multiorgan dysfunction and increased risk of atrial fibrillation, stroke, and heart failure. Atrial cardiomyopathy (ACM) - defined as any structural, contractile, or electrical abnormality of the atria - is an increasingly recognized contributor to cardiovascular morbidity and mortality in this population. Despite growing interest in both conditions, their interplay remains poorly understood, limiting effective preventive strategies and risk-stratification approaches for this high-risk group.\n\nCKM staging offers a practical framework for anticipating ACM onset and progression. Because adiposity-driven inflammation, insulin resistance, hypertension, and early kidney injury act as upstream drivers in CKM, the left atrium becomes an early indicator of hemodynamic load and fibrosis - often preceding sustained atrial fibrillation. Early non-invasive detection of ACM across CKM stages could shift care from treating complications to modifying the underlying substrate.\n\nThis prospective observational single-center cohort study aims to phenotype ACM non-invasively across all CKM stages at first diagnosis, using standard 12-lead ECG, advanced transthoracic echocardiography with speckle-tracking, a mechanistically selected biomarker panel (NT-proBNP, MR-proANP, Fetuin-A, FGF23), and cardiac MRI.\n\nAdults aged 18 years or older presenting for cardiovascular evaluation are enrolled and grouped as CKM with ACM (study group) versus CKM without ACM (control group). All participants undergo a single standardized baseline evaluation including clinical examination, 12-lead ECG with Bayés interatrial block grading, comprehensive laboratory panel, and advanced echocardiography including left atrial global longitudinal strain by speckle-tracking.\n\nPrimary objective: characterize the relationship between ACM and CKM syndrome stages using non-invasive parameters at first diagnosis. Secondary objectives include assessment of clinical, biological, ECG, and imaging profiles of ACM in CKM; evaluation of left atrial function across CKM stages; examination of Bayés interatrial block correlations and the impact of SGLT2 inhibitors and GLP-1 receptor agonists on left atrial remodeling in HFpEF; and identification of independent ACM risk factors incorporating the full biomarker panel.\n\nStatistical analyses include multivariable logistic regression, biomarker ROC analyses, and penalized regression for derivation of a pragmatic ACM risk score with internal validation. Expected outputs include prevalence estimates, effect sizes for ACM and CKM joint categories, biomarker performance metrics, and a clinic-ready checklist for risk-stratified prevention in outpatient settings.",[64,65,66,67,29],"Cardiovascular-Kidney-Metabolic Syndrome","Atrial Cardiomyopathy","Atrial Fibrillation","Chronic Kidney Disease",[69,70,71,72,73,74,75,76,77,66,67],"atrial cardiomyopathy","CKM syndrome","on-invasive evaluation","atrial remodeling","Bayés interatrial block","speckle tracking","Fetuin-A","MR-proANP","FGF23","2026-07-05",{"date":42,"type":43},{"date":40,"type":21},{"date":82,"type":21},"2028-04",{"name":84,"class":85},"Grigore T. Popa University of Medicine and Pharmacy","OTHER",{"id":87,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":25,"conditions":90,"keywords":91,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":51},"100617066",{"count":20,"type":21},[24],[27,28,29,30,31,32],[34,35,36,37,38],"2026-07-01",{"date":94,"type":43},"2026-07-02",{"date":96,"type":21},"2026-07-07",{"date":47,"type":21},{"name":49,"class":50},{"id":100,"slug":4,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":127,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":51},"100643981","NCT07669168","Health Ahead Comparative Effectiveness Study","Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening","HACE","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up.\n\nExclusion Criteria:\n\n\\- Age under 18 years.",true,{"count":108,"type":21},1000000,[110],"NA","The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.\n\nThe first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.",[113,114,115,116,117,118,119,120,29,121,122,123,124,125,126],"Health Services Accessibility","Rural Health","Medically Underserved Area","Preventive Health Services","Patient Participation","Health Behavior","Aging","Cardiovascular Diseases","Cognitive Dysfunction","Frailty","Activities of Daily Living","Health Related Quality of Life","Health Equity","Telemedecine",[128,129,130,131,132,125,114,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149],"Sequential Platform Trial","Interactive Health Report","Health Activation","Mobile Health Screening","Comparative Effectiveness","Medically Underserved","Preventive Medicine","Patient Engagement","Cardiopulmonary Exercise Testing","Body Composition","DEXA","Health Ahead Bus","Mobile Clinic","Automated Screening","Medical Droids","Biological Age","Healthspan","Longevity","Life Expectancy","Chronic Disease","Cost-Effectiveness","Health Services Research","RECRUITING","2026-06-20",{"date":153,"type":43},"2026-06-25",{"date":155,"type":21},"2026-06-09",{"date":157,"type":21},"2099-12-31",{"name":159,"class":160},"William Brandenburg, MD","INDUSTRY",{"id":162,"slug":4,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":106,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100524721","NCT06112418","A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events","A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events","TRANSFORM","Inclusion Criteria:\n\n1. Provided electronic or written informed consent\n2. Men \\> 55, women \\> 65 years of age\n3. Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and\u002For fasting glucose 100-125 mg\u002FdL \\[5.6-6.9 mmol\u002FL\\]) and\u002For metabolic syndrome. Metabolic syndrome is defined as \\> 3 of the following criteria (International Diabetes Federation 2006):\n\n   * Body mass index ≥ 27 kg\u002Fm2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)\n   * Fasting triglycerides ≥ 150 mg\u002FdL (1.7 mmol\u002FL) or treated hypertriglyceridemia\n   * HDL-cholesterol (HDL-C) \\\u003C 40 mg\u002FdL (1.03 mmol\u002FL) in men, \\\u003C50 mg\u002FdL (1.29 mmol\u002FL) in women or treatment for this lipid abnormality\n   * Systolic blood pressure (BP) ≥ 130 and\u002For diastolic BP≥ 85 mm Hg and\u002For treated hypertension\n   * Fasting blood glucose ≥ 100 mg\u002FdL (5.6 mmol\u002FL) or HbA1c ≥ 5.7%\n4. Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group\n\nExclusion Criteria:\n\n1. History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure\n2. Planned arterial revascularization\n3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:\n\n   1. eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org\u002Fprofessionals\u002Fkdoqi\u002Fgfr\\_calculator)\n   2. Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.\n   3. Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment\n   4. Weight \\> 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site\n   5. Inability to hold breath for \\> 10 seconds\n   6. Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., \\> 80 beats per minute at screening or prior to CCTA)\n   7. Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA\n   8. Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA\n4. Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy \\\u003C 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)","55 Years",{"count":170,"type":21},7500,[110],"TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.",[174,175,29],"Diabetes Mellitus, Type 2","PreDiabetes","2026-06-15",{"date":178,"type":43},"2026-06-16",{"date":180,"type":43},"2024-03-06",{"date":182,"type":21},"2029-03-05",{"name":184,"class":160},"Cleerly, Inc.",124,{"id":187,"slug":4,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":106,"sex":16,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":51},"100609572","NCT07216326","Our Voices Matter: Intervention for Depression in Youth","Our Voices Matter: Racial Justice Activism Intervention to Address Structural Racism and Prevent Depression in Black and Latinx Youth","OVM","Inclusion Criteria:\n\n1. 15-20 years old\n2. Identify as Black and\u002F or Latinx\n3. Speak English\n\nExclusion Criteria:\n\n1. Younger than 15 years old, or older than 20 years old\n2. Unable to attend the in-person sessions\n3. Non-fluent English speaker\n4. Do not identify as Black or Latinx","15 Years","20 Years",{"count":196,"type":21},300,[110],"Over 15 million people participated in racial justice protests nationwide during 2020-2021 spotlighting activism as a collective tool against structural racism and discrimination (SRD). SRD manifests as policies and practices (e.g., redlining, voter suppression, mass incarceration) that produce hostile environments that contribute to psychological distress, elevated allostatic load, and an elevated risk for chronic diseases and premature death, concentrated within Black and Latinx populations. While the connection between SRD and health is well documented, few studies provide evidence on strategies to reduce SRD and mitigate consequences on psychological and physiological outcomes. Thus, there is a critical need to rigorously test interventions that improve the mental and physical health of Black and Latinx populations, beginning in adolescence. The study's specific aims are to 1) Determine whether a racial justice activism behavioral intervention prevents and reduces depressive symptoms in Black and Latinx adolescents and young adults and 2) Determine whether a racial justice activism behavioral intervention lowers allostatic load scores in Black and Latinx adolescents and young adults. To accomplish these aims, the team will conduct a stage II group-based, multi-component, and multilevel randomized behavioral clinical trial. The investigators will collect psychological and physiological measures at baseline, then at defined intervals for 2 years post the racial justice activism intervention.",[200,201,29],"Depressive Symptoms","Allostatic Load",[203,204,205,206,207,208,209,210,211],"mental health","youth intervention","allostatic load","stress","depressive symptoms","depression","metabolic syndrome","prevention","inflammation","2026-06-12",{"date":176,"type":43},{"date":215,"type":43},"2025-06-06",{"date":217,"type":21},"2028-12-29",{"name":219,"class":85},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":221,"slug":4,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":51},"100641794","NCT07653048","Personality Traits and Biochemical Risk Phenotypes","Personality Traits and Biochemical Risk Phenotypes in Adults Undergoing Routine Health Assessment","PHEBiP","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing routine health assessment\n* Completion of the Five-Factor Personality Inventory (FFPI)\n* Availability of routine laboratory test results\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Incomplete FFPI assessment\n* Missing or incomplete laboratory data\n* Refusal or inability to provide informed consent",{"count":228,"type":21},1000,"This prospective observational study investigates the association between personality traits and routine laboratory abnormalities in adults undergoing routine health assessment. Personality traits are assessed using the Five-Factor Personality Inventory (FFPI), while biochemical data are obtained from routine laboratory testing, including markers of glycemic status, liver function, lipid metabolism, renal function, and complete blood count parameters.\n\nThe primary objective of the study is to evaluate the association between FFPI personality trait scores and the total number of laboratory abnormalities identified during routine clinical evaluation. Secondary analyses will examine associations between personality traits and glycemic status, fasting plasma glucose concentration, liver function markers, lipid profile parameters, renal function indicators, complete blood count parameters, and the total number of laboratory abnormalities.\n\nThe findings may contribute to a better understanding of the relationship between psychological characteristics and biological health indicators and may support the development of more personalized approaches to health promotion, risk assessment, and disease prevention.",[231,232,29],"Prediabetes","Hyperglycemia",[234,235,231,232,236,237,238,239],"Personality Traits","Biomarkers","Occupational Health","Five-Factor Personality Inventory","Laboratory Abnormalities","Routine Health Assessment","2026-06-11",{"date":242,"type":43},"2026-06-17",{"date":244,"type":43},"2024-10-01",{"date":246,"type":21},"2027-09-01",{"name":248,"class":85},"Medical Center TOPMED",{"id":250,"slug":4,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":258,"conditions":259,"keywords":264,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":4,"leadSponsor":273,"locationsCount":51},"100143840","NCT01143480","Study of the Effect of Innate on the Inflammatory Response to Endotoxin","Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin","* INCLUSION CRITERIA:\n* Male or female 18 years of age or older\n* Participants must be able to understand and provide written informed consent to participate in the study\n* Participants must be able to travel to the CRU\n* Willing and able to fast after midnight the night prior to their study appointment.\n* Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control).\n\nEXCLUSION CRITERIA:\n\n* Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to enrollment visit (e.g., Motrin, ibuprofen, naproxen, and Advil)\n* Use of acetaminophen (Tylenol) within 5 days prior to enrollment visit\n* Use of cholesterol lowering drugs (statins) within 30 days prior to enrollment visit (e.g., Zocor, Mevacor, Lipitor, and Crestor)\n* Use of immunosuppressants or other immune-modifying drugs \\[e.g., Rituxan, Humira, Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), and Azathioprine (Imuran)\\], Monoclonal antibodies \\[e.g., infliximab (Remicade)\\], and corticosteroids (e.g., prednisone, prednisolone and dexamethasone)\n* Current treatment for cancer with chemotherapy or radiation\n* Confirmed or suspected immunosuppressive or immunodeficient condition\n* GI or respiratory Illness within 5 days prior to enrollment visit, including cold or allergies\n* Smoked tobacco, chewed tobacco or used electronic cigarettes within 2 weeks prior to enrollment visit (for participants who provide a urine specimen, this will be defined by urine cotinine \\>200 ng\u002FmL at visit)\n* Alcohol consumption greater than 2 standard drinks (1 standard drink contains 15 g of ethanol) per day within the last 24 hours prior to the enrollment visit\n* Body weight \\\u003C 50 kg (\\\u003C110 lbs)\n* Temperature \\> 37.6 C; blood pressure \\\u003C 90\u002F50 mm Hg or \\> 170\u002F95 mm Hg; pulse rate \\\u003C 50 or \\>100 beats\u002Fminute\n* Pregnant or suspected pregnancy\n* Chronic Kidney Disease\n\nThe PI may review medication use on a case by case basis and make a medical determination on the participant s eligibility. In these cases, the PI determination will be documented in the participant s chart.","100 Years",{"count":257,"type":21},725,"Background:\n\n\\- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers.\n\nObjectives:\n\n\\- To examine how specific genes and proteins in blood cells respond to environmental exposures.\n\nEligibility:\n\n\\- Healthy volunteers between 18 and 45 years of age.\n\nDesign:\n\n* The study will involve one visit of 45 to 60 minutes.\n* Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking.\n* Participants will provide a blood sample for research purposes.",[260,261,29,262,263],"Asthma","Atherosclerosis","Insulin Resistance","Cancer",[265,266,267,30,268],"Endotoxin","Innate Immunity","Natural History","HV","2026-06-10",{"date":240,"type":43},{"date":272,"type":43},"2012-07-30",{"name":274,"class":50},"National Institute of Environmental Health Sciences (NIEHS)",{"id":276,"slug":4,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":283,"conditions":284,"keywords":295,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":51},"100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",{"count":108,"type":21},"The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[119,285,286,146,120,287,121,29,122,288,289,290,123,124,291,292,293,125,294],"Mortality","All-cause Mortality","Neoplasms","Musculoskeletal Disease","Neurodegenerative Disease","Dementia","Disability Physical","Environmental Exposure","Occupational Diseases","Social Determinants of Health",[296,297,298,299,300,301,302,303,304,305,306,307,308,125,309,310,136,137,134,144,311,312,313,314,315],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model",{"date":176,"type":43},{"date":318,"type":43},"2026-04-25",{"date":157,"type":21},{"name":321,"class":160},"Longevity Metrics, Inc.",{"id":323,"slug":4,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":329,"conditions":330,"keywords":336,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":51},"100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":108,"type":21},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[119,331,332,285,29,120,121,333,287,122,123,334,291,335,290],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[145,136,137,134,337,309,311,144,146,338,339,340,310,341,306,312],"Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":240,"type":43},{"date":344,"type":43},"2025-02-09",{"date":157,"type":21},{"name":321,"class":160},{"id":348,"slug":4,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":51},"100571091","NCT06715735","Theory-based Health Behaviour Change Intervention in Individuals of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of A Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension), and CKD;\n* Participants are capable of understanding and providing informed consent, their cognitive function will be screened by the abbreviated mental test with a score higher than seven;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese.\n\nExclusion Criteria:\n\n* Participants who have medical contraindications to exercise, including walking;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":354,"type":21},160,[110],"This study will adopt a 2-arm, pretest-posttest, and assessor-blind RCT design to examine the effectiveness of a theory-based health behaviour change intervention on WC (primary outcome), kidney function (eGFR, primary outcome), dietary behaviour, PA, exercise capacity, and self-efficacy of dietary behaviour and PA among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nA total of 160 adults with metabolic syndrome and chronic kidney disease will be recruited, with 80 participants in each group. Data will be collected at 3-time points (baseline, immediate post-intervention and 1-month post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[358,29],"Chronic Kidney Diseases",[29,67,360,361,362,363],"Waist Circumference","Kidney Function","Behaviour Change Intervention","Health Action Process Approach",{"date":240,"type":43},{"date":366,"type":43},"2024-12-20",{"date":368,"type":21},"2026-10-30",{"name":370,"class":85},"Chinese University of Hong Kong",{"id":372,"slug":4,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":51},"100556643","NCT06527768","Theory-based Health Behaviour Change Intervention in Patients of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of a Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension) and CKD;\n* No medical contraindications to exercise, including walking;\n* Participants are capable of understanding and providing informed consent;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese;\n* Stay in Chengdu during the study period.\n\nExclusion Criteria:\n\n* Participants who cannot perform brisk walking exercise;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Participants who have a cognitive impairment, which will be screened by the abbreviated mental test with a score lower than seven;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":378,"type":21},40,[110],"The pilot study will adopt a 2-arm, pretest-posttest, and assessor-blind randomized controlled trial design to examine the feasibility and acceptability of a theory-based health behaviour change intervention and examine its effects on waist circumference (primary outcome), kidney function (estimated glomerular filtration rate, urine albumin-to-creatinine ratio, primary outcome), dietary behaviour, physical activity, exercise capacity and self-efficacy of diet behaviour and physical activity among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nResearchers will compare the theory-based health behaviour change intervention to usual care to see if the theory-based health behaviour change intervention can reduce waist circumference and preserve kidney function over three months.\n\nA total of 40 adults with metabolic syndrome and chronic kidney disease will be recruited, with 20 participants in each group. Data will be collected at two-time points (baseline and immediate post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[358,29],[29,67,360,361,362],{"date":240,"type":43},{"date":385,"type":43},"2024-07-31",{"date":387,"type":21},"2026-07-31",{"name":370,"class":85},{"id":390,"slug":4,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":396,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":399,"conditions":400,"keywords":405,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":419,"locationsCount":51},"100643167","NCT07643376","Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management","Evaluation of Postoperative Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms in Body Weight Management After Laparoscopic Sleeve Gastrectomy","METABAR","Inclusion Criteria:\n\n* Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month\n* Aged between 19-50 years\n* BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities\n* Signed informed consent form\n* Non-smoker and non-alcohol dependent\n\nExclusion Criteria:\n\n* Did not undergo or is not planned to undergo LSG\n* Outside the age range of 19-50 years\n* Did not sign the informed consent form\n* BMI \\\u003C40 kg\u002Fm² or BMI \\\u003C35 kg\u002Fm² without obesity-related comorbidities\n* Smoker or alcohol dependent\n* Has an inflammatory disease\n* Currently using probiotics, antibiotics, or fiber supplements\n* Has a psychiatric disorder","19 Years","50 Years",{"count":378,"type":21},"This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.\n\nObesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.\n\nIn this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:\n\n* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels\n* Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels\n* Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)\n* Anthropometric measurements: body weight, height, waist and hip circumference, BMI\n* Nutritional intake: 3-day dietary records\n\nThe study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.",[401,402,403,404,29],"Obesity, Morbid","Bariatric Surgery","Intestinal Permeability","Gastrointestinal Symptoms",[406,407,408,409,410,411,412,413],"Laparoscopic Sleeve Gastrectomy","Zonulin","Secretory IgA","Lipopolysaccharide","GSRS","Body Weight Management","Gut microbiota","Postoperative Metabolic Parameters","2026-06-08",{"date":240,"type":43},{"date":92,"type":21},{"date":418,"type":21},"2027-02-01",{"name":420,"class":85},"Toros University",{"id":422,"slug":4,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":51},"100424854","NCT04812314","Exercise Effects on Adipose Tissue Structure and Function","LG","Inclusion Criteria:\n\n* Age: 18-40\n* Body Mass Index: 27-45 kg\u002Fm2\n* No regularly planned exercise\u002Fphysical activity for at least 6 months\n* Women must have regularly occurring menses and must be premenopausal\n\nExclusion Criteria:\n\n* Evidence\u002Fhistory of cardiovascular or metabolic disease\n* Medications known to affect lipid or glucose metabolism, or inflammation\n* Weight instability ≥ ± 6 pounds in the last 3 months\n* Tobacco or e-cigarette users\n* Women must not be pregnant or actively lactating","40 Years",{"count":429,"type":21},46,[110],"Participants will be randomized into one of two different experimental groups: 1) Exercise group and 2) No exercise (control group). Subject participation in the study will involve a series of metabolic tests before and after participants undergo a 10% weight loss program (with or without exercise training depending on group randomization). After completing this weight loss portion of the study, participants will then be required to adhere to a high calorie diet program to regain half of the weight the participant lost - followed by the same series of metabolic tests.",[433,29,434,262,435,436],"Obesity","Metabolic Disease","Weight Loss","Weight Gain","2026-06-02",{"date":439,"type":43},"2026-06-04",{"date":441,"type":43},"2021-03-01",{"date":443,"type":21},"2030-03-01",{"name":445,"class":85},"University of Michigan",{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":452,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":458,"conditions":459,"keywords":463,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":470,"leadSponsor":472,"locationsCount":474},"100638318","NCT07625332","Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)","Pilot Study of Tolerability and Preliminary Efficacy of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n* Adults aged 21-75 years (male or female)\n* Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI)\n* Wheelchair user for community mobility\n* Injury level of tetraplegia (cervical level) or paraplegia (all levels)\n* SCI-specific obesity indicated by waist circumference ≥94 cm\n* Resting heart rate \\>45 bpm based on 10 measurements over 10 minutes\n* Without clinically significant cardiovascular abnormalities as indicated by 12-lead ECG\n* Tolerable bowel routine indicated by a score of \\\u003C10 on the International SCI Bowel Function Data Set (ISCI-BDS)\n* Metabolic Syndrome (MetS) defined by the presence of at least three of the following: (1) obesity indicated by SCI-specific waist circumference ≥94 cm, (2) elevated fasting glucose ≥100 mg\u002FdL, (3) dyslipidemia: high triglycerides ≥150 mg\u002FdL or low HDL cholesterol \\\u003C40 mg\u002FdL for men and \\\u003C50 mg\u002FdL for women, (4) C-reactive protein (CRP) levels \\>1 mg\u002FdL\n* Able to understand and communicate in English at the level of describing adverse event frequency and severity and completing validated outcome measures\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n* Diagnosis of neurological injury or condition other than SCI\n* Progressive condition that would be expected to change neurological status\n* Signs and symptoms of cardiovascular disease or cardiac arrhythmias\n* Resting heart rate \\\u003C45 bpm\n* Score of 10 or greater on the ISCI-BDS v2.1 indicating moderate to severe neurogenic bowel dysfunction\n* Severe concurrent medical disease, condition, or illness judged to be contraindicated by the site physician\n* Psychopathology documented in the medical record or history that may conflict with study objectives\n* Pregnancy (participant reported or determined by clinical lab test), women who plan to become pregnant, or women who are nursing during the study\n* Active cancer or currently in treatment for cancer\n* Triglyceride levels ≥400 mg\u002FdL\n* Chronic use of medications with known or probable interactions with galantamine\n* Enrolled in another research study that is likely to interfere with conduct or results of the current study\n* Any other reason the site physician feels that participation is contraindicated","21 Years","75 Years",{"count":455,"type":21},60,[24,457],"PHASE3","The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.",[460,461,462,29],"Spinal Cord Injury","Traumatic Spinal Cord Injury","Paraplegia and Tetraplegia",[464,465,466,209],"spinal cord injury","tetraplegia","paraplegia","2026-05-28",{"date":439,"type":43},{"date":176,"type":21},{"date":471,"type":21},"2027-12",{"name":473,"class":85},"Northwell Health",3,{"id":476,"slug":4,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":16,"minAge":427,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":484,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":497,"leadSponsor":499,"locationsCount":4},"100640428","NCT07620886","Effects of Postprandial Walking and Resistance Snacking on Glucose Responses in Adults With Metabolic Syndrome","Effects of Postprandial Walking and Brief Resistance Exercise Snacks on Continuous Glucose and Heart Rate Variability Responses in Adults With Metabolic Syndrome and Prediabetes: A Randomized Crossover Trial","BITE","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Adults aged 40 to 65 years\n* Presence of metabolic syndrome\n* Fasting glucose of 100 mg\u002FdL or higher or HbA1c of 5.7% or higher\n* Not regularly engaged in structured exercise training, defined as less than 150 minutes per week during the past year\n* Able to consume the standardized study meals\n* Able to wear a continuous glucose monitor and a chest strap heart rate monitor\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* History of major cardiovascular, cerebrovascular, respiratory, renal, hepatic, neurological, or other severe medical conditions that may affect study participation.\n* Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg.\n* Current use of medications associated with a high risk of hypoglycemia, such as insulin or sulfonylureas.\n* Initiation or dose change of insulin or oral glucose-lowering medications within the past 3 months.\n* Initiation or dose change of medications for hypertension, dyslipidemia, or diabetes within the past 3 months.\n* Musculoskeletal, neurological, or orthopedic conditions that limit safe participation in walking or body-weight resistance exercise, including severe knee, hip, back, or ankle pain.\n* Regular participation in moderate-to-vigorous exercise of 150 minutes or more per week during the past year.\n* Difficulty consuming the standardized study meals, including food allergy, dietary restrictions, or severe gastrointestinal symptoms.\n* Difficulty wearing a continuous glucose monitor or history of severe skin irritation or allergy to adhesive sensors.\n* Difficulty wearing a chest strap heart rate monitor or skin problems at the chest strap site.\n* Pregnancy or planned pregnancy.\n* Acute illness, infection, surgery, or hospitalization within the past month.\n* Current participation in another interventional study.\n* Any condition judged by the investigator to make participation unsafe or inappropriate.\n\nExclusion Criteria:\n\n\\-","65 Years",{"count":7,"type":21},[110],"This study will examine whether light physical activity after meals can improve 24-hour glucose responses in adults with metabolic syndrome and prediabetes.\n\nParticipants will complete three experimental conditions in a randomized crossover order: prolonged sitting, 15 minutes of postprandial walking, and brief resistance exercise snacks consisting of squats and calf raises performed every 20 minutes during the postprandial period. Continuous glucose monitoring will be used to assess 24-hour glucose responses, and heart rate variability will be measured during the 2-hour postprandial period to evaluate acute autonomic responses.\n\nThe main outcome is 24-hour mean glucose derived from continuous glucose monitoring.",[29,231],[488,489,490,491,492,231,493],"Continuous glucose monitoring","Postprandial glucose","Exercise snack","Resistance exercise","Heart rate variability","Metabolic syndrome","2026-05-27",{"date":437,"type":43},{"date":176,"type":21},{"date":498,"type":21},"2026-10",{"name":500,"class":85},"Seoul National University",{"id":502,"slug":4,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":531},"100638613","NCT07621640","Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)","Brown Adipose Tissue as a Mechanistic Determinant of GLP-1 Receptor Agonist Treatment Response in Adults With Obesity: A Multicenter Prospective Cohort Study Using ¹⁸FDG-PET\u002FCT and Cold Stimulation Protocol","BAT-Sema","Inclusion Criteria:\n\n1. Age 20-70 years at the time of enrollment\n2. Initiating semaglutide (Wegovy) treatment for obesity (newly starting treatment)\n3. BMI ≥ 27 kg\u002Fm² with at least one weight-related comorbidity:\n\n   * Hypertension (SBP ≥130 or DBP ≥80 mmHg, or on antihypertensive medication)\n   * Dyslipidemia (LDL-C ≥130, TG ≥150, or low HDL-C, or on lipid-lowering medication)\n   * Non-alcoholic fatty liver disease (NAFLD\u002FMASLD, confirmed by imaging or ALT\u002FAST ≥1.5× ULN)\n   * Obstructive sleep apnea (AHI ≥5\u002Fhr or clinically diagnosed)\n   * Established cardiovascular disease (CAD, stroke, PAD)\n   * Obesity-related osteoarthritis of knee or hip with functional impairment OR BMI ≥ 30 kg\u002Fm² (regardless of comorbidity)\n4. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 or type 2 diabetes mellitus\n2. History of neck surgery or radiation therapy to the neck\n3. Use of anti-obesity medications within 1 month prior to enrollment, or current use of beta-adrenergic blocking agents\n4. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n5. Active malignancy, severe renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), severe hepatic disease, or other severe endocrine disorders\n6. Pregnancy or breastfeeding\n7. Severe psychiatric illness or cognitive impairment precluding informed consent\n8. Contraindication to MRI (pacemaker, cochlear implant, non-MRI-compatible implants)\n9. Severe claustrophobia","70 Years",{"count":510,"type":21},80,[110],"This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly injectable weight loss medication. Participants who are starting semaglutide treatment will undergo ¹⁸FDG-PET\u002FCT imaging before and after 24 weeks of treatment. Prior to each PET\u002FCT scan, participants will wear a water-circulating cooling vest to activate BAT. By measuring BAT activity at baseline and comparing it with the degree of weight loss and metabolic improvement at 24 weeks, the investigators aim to identify BAT as a predictive biomarker for personalized obesity treatment.",[433,29,514],"Brown Adipose Tissue",[516,517,518,433,519,520,521,522,523],"Brown adipose tissue","Semaglutide","GLP-1 receptor agonist","FDG-PET\u002FCT","BAT","Biomarker","Weight loss","PDFF",{"date":437,"type":43},{"date":526,"type":21},"2026-06",{"date":528,"type":21},"2031-02",{"name":530,"class":85},"Hallym University",2,{"id":533,"slug":4,"hasResults":11,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":11,"sex":539,"minAge":17,"maxAge":427,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":550,"locationsCount":51},"100581596","NCT06852365","Combined Oral Contraceptive Pill and Resistance Starch","Resistant Starch Usage in Polycystic Ovary Syndrome: Impact on Cardiometabolic Dysfunction and the Gut Microbiome (CORS-PCOS)","COR-PCOS","Inclusion Criteria:\n\n1. Women between ages of 18-40 years with BMI greater than or equal to 25 kg\u002Fm² to less than or equal to 48 kg\u002Fm² diagnosed with PCOS defined by the Rotterdam criteria based on a history of chronic anovulation (8 or fewer periods), androgen excess \\[defined as total serum testosterone, free testosterone or a FAI greater than or equal to 90% of the upper limit of normal) or hirsutism (Ferriman-Gallwey score greater than 6 for Hispanics\u002F Black and greater than or equal to 2 for women of Asian descent)\\] and polycystic ovaries as defined by a pelvic ultrasound (20 or more follicles or ovarian vol greater than 10cm3) or elevated AMH.\n2. For women with more regular bleeding patterns, but who are suspected to be experiencing periodic anovulatory bleeding, a midluteal progesterone (P4) level less than 3ng\u002FdL will be evidence of ovulatory dysfunction and qualify as anovulation.\n3. Women with only hyperandrogenic PCOS phenotype (hyperandrogenism + one more criteria) will be included to decrease the heterogeneity of the cohort and as metabolic risks are increased in these women compared to normo-androgenic women with PCOS.\n4. Subjects should be willing to avoid pregnancy for the entire duration of the study.\n\nExclusion Criteria:\n\n1. Subjects with other causes for irregular menses such as pregnancy, lactation, untreated hypothyroidism, untreated hyperprolactinemia and premature menopause.\n2. Subjects with late onset adrenal hyperplasia\n3. Subjects with history of bariatric surgery\n4. Those who are unable to comply with the study procedures, for instance due to mental illness, substance abuse, or participation in other studies.\n5. Subjects taking medications that affect weight or metabolic parameters (e.g. lipid lowering medications).\n6. History of Crohn's disease and ulcerative colitis as well as current use of probiotics and laxatives are excluded.\n7. Subjects could not have taken antibiotics for at least 3 months prior to randomization visit.\n8. Subjects with greater than 20 g\u002Fday of dietary fiber intake based on pre-screening ASA-24 survey will be excluded.\n9. Subjects with medical conditions that are contraindications to use of OCP and other medical conditions such as:\n\n   1. Type 1 or 2 diabetes\n   2. liver disease or dysfunctional liver (AST\u002FALT greater than 2x normal or a total bilirubin greater than 2.5 mg\u002FdL)\n   3. renal disease (BUN greater than 30 mg\u002FdL or serum creatinine greater than 1.4 mg\u002FdL)\n   4. severe anemia (hemoglobin less than 10 mg\u002FdL)\n   5. alcohol abuse\n   6. poorly controlled hypertension\n   7. TG greater than 250 mg\u002Fdl\n   8. chronic inflammatory conditions such as psoriasis\n   9. history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; known heart disease (New York Heart Association Class II or higher)\n   10. history of cervical carcinoma, endometrial carcinoma, or breast carcinoma, adrenal or ovarian tumor secreting androgens, and Cushing's syndrome -","FEMALE",{"count":20,"type":21},[24],"This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.",[29,544],"Polycystic Ovary Syndrome",{"date":546,"type":43},"2026-06-01",{"date":548,"type":43},"2025-06-10",{"date":82,"type":21},{"name":551,"class":85},"University of Pennsylvania",{"id":553,"slug":4,"hasResults":11,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":557,"enrollmentInfo":558,"targetDuration":4,"studyType":22,"phases":560,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":51},"100609751","NCT07218653","Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome","Inclusion Criteria (Healthy Controls):\n\n* 18-45 years old\n* Normal fasting values for blood glucose (less than 100 g\u002Fdl)\n* Normal values for lipids (LDL cholesterol less than 130 mg\u002Fdl, triglycerides less than 150 mg\u002Fdl) and HDL (men greater than 40, women greater than 50 mg\u002Fdl)\n* Women must have a predictable menstrual cycle. Females will be studied on cycle days 1-7 to minimize sex hormone differences and their potential confounding effects on vascular outcomes. Oral contraceptives are allowed, and women will be studied during their placebo phase.\n\nInclusion Criteria (Participants with Metabolic Syndrome):\n\n* 18-45 years old\n* Meet at least 3 of the 5 ATP MetSyn criteria. These are:\n\n  1. Waist circumference greater than 102 cm (males) or 82 cm (females)\n  2. Triglycerides greater than 150 mg\u002FdL\n  3. HDL cholesterol less than 40 mg\u002FdL (males) or 50 mg\u002FdL (females)\n  4. Blood pressure greater than or equal to 130\u002F85 mmHg\n  5. Fasting plasma glucose greater than 110 mg\u002FdL\n\nExclusion Criteria (Healthy Controls):\n\n* Body Mass Index (BMI) greater than or equal to 25 kg\u002Fm2\n* Blood pressure over 130\u002F80 mmHg\n* Meeting any of the 5 MetSyn criteria listed above.\n\nExclusion Criteria (all participants):\n\n* Current smoker, defined as more than 5 cigarettes over past 30 days\n* Current diagnosis or history of:\n\n  * peripheral vascular disease\n  * hepatic disease\n  * renal disease\n  * lung disease\n  * gastrointestinal disorders\u002Fbleeding\n  * hematologic disease\n  * stroke\n  * myocardial infarction\n  * coronary heart disease\n  * congestive heart failure\n  * heart surgery\n  * sleep apnea\n  * autoimmune diseases\n  * HIV\n  * traumatic brain injury, concussion, stroke, or seizures\n  * Asthma\n  * Polycystic ovarian syndrome\n  * Type II diabetes\n  * Currently pregnant or breastfeeding\n  * Current musculoskeletal injury\n  * Medication use known to influence cardiovascular function, other than contraceptive hormones. Broadly, the classes of drugs relate to treating blood pressure, diabetes, cholesterol.\n  * Claustrophobia\n* Lactose intolerance\n* Magnesium-restricted diet","45 Years",{"count":559,"type":21},72,[561],"EARLY_PHASE1","This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.",[29],[565,566,567,29,568],"Cerebral Blood Flow","CBF","COX","MetSyn","2026-05-20",{"date":571,"type":43},"2026-05-26",{"date":573,"type":21},"2026-07",{"date":575,"type":21},"2031-07",{"name":577,"class":85},"University of Wisconsin, Madison",{"id":579,"slug":4,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":605,"leadSponsor":607,"locationsCount":51},"100639892","NCT07606872","Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes","A Prospective Interventional Clinical Validation Study of the Snouda Metabolic Score (SMS) as a Phenotyping and Protocol-Targeting Instrument in Adults With Type 2 Diabetes Mellitus","SMS-VAL","Inclusion Criteria:\n\n* Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider\n* Age 18 years or older\n* HbA1c between 6.5% and 11.0% at baseline\n* Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas)\n* Ability to access and use the diabetesreversal.io digital platform\n* Willingness to perform daily self-monitoring of blood glucose\n* Willingness to complete laboratory blood tests (Genesis Biomarker Panel) at baseline and Week 24 at own expense\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA)\n* Currently pregnant or breastfeeding\n* Currently using insulin therapy\n* Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide)\n* HbA1c greater than 11.0% at baseline\n* History of severe hypoglycemia requiring third-party assistance in the past 12 months\n* Active malignancy or receiving chemotherapy or radiation therapy\n* Severe renal impairment (eGFR less than 30 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment\n* Active eating disorder\n* Any condition that in the opinion of the investigator would make participation unsafe or interfere with study completion",{"count":586,"type":21},150,[110],"This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.\n\nOnce classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study.\n\nThe main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication.\n\nThe study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.",[590,262,29],"Type 2 Diabetes Mellitus (T2DM)",[592,593,594,595,596,597,598,599,600,601],"Diabetes reversal","Metabolic phenotyping","Snouda Metabolic Score","Lifestyle intervention","HbA1c reduction","Intermittent fasting","Low-carbohydrate diet","Chronic inflammation","Mitochondrial dysfunction","Gut microbiome","2026-05-19",{"date":571,"type":43},{"date":526,"type":21},{"date":606,"type":21},"2027-03",{"name":608,"class":85},"Salah Snouda",{"id":610,"slug":4,"hasResults":11,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":616,"enrollmentInfo":617,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":619,"conditions":620,"keywords":623,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":4},"100638273","NCT07584330","AI-Driven Metabolic Cohort in Overweight\u002FObese Chinese Adults","Chinese Overweight\u002FObese - Diabetes Metabolic Spectrum Cohort: An Artificial Intelligence-Driven Prospective Study","COMET-AI","Inclusion Criteria:\n\n1. Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements.\n2. Age between 18 and 60 years (inclusive).\n3. Meets at least one of the following overweight\u002Fobesity criteria: a) BMI ≥ 24 kg\u002Fm²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.\n4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.\n2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \\\u003C 0.1 mIU\u002FL with FT4 \\> upper normal limit; hypothyroidism: TSH \\> 10 mIU\u002FL), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.\n3. Severe liver disease (Child-Pugh class B or C).\n4. Renal insufficiency (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n5. Severe cardiac dysfunction (New York Heart Association class III or IV).\n6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke).\n7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%).\n8. Active malignancy (diagnosed or treated within the last 3 years).\n9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea).\n10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder).\n11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency).\n12. Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes.\n13. Pregnancy or planned pregnancy during the study period.\n14. History of or planned organ transplantation.\n15. Inability to operate the AI-based system or comply with follow-up procedures.\n16. Concurrent participation in another interventional clinical trial that may influence the results of this study.\n17. Unwilling or unable to provide informed consent.","60 Years",{"count":618,"type":21},2800,"The goal of this observational cohort study is to delineate the five-year dynamic trajectories of metabolic phenotypes in Chinese adults with overweight or obesity, with or without type 2 diabetes, focusing on transition rates from metabolically healthy overweight\u002Fobesity to unhealthy overweight\u002Fobesity or to type 2 diabetes, as well as the incidence and progression of diabetic complications and cardiovascular events in those with type 2 diabetes and overweight\u002Fobesity. Researchers will compare three phenotype groups, namely metabolically healthy overweight\u002Fobesity, metabolically unhealthy overweight\u002Fobesity, and type 2 diabetes with overweight\u002Fobesity, to assess differences in metabolic parameter changes, complication rates, and cardiovascular risk. Participants will use a digital health management platform for data upload and lifestyle support, and will complete comprehensive health assessments at baseline, at 2.5 years, and at 5 years, along with annual light follow-ups.",[621,174,622,29],"Overweight and Obesity","Prediabetic State",[621,624,29,625,626,627],"Type 2 Diabetes Mellitus","Metabolic Phenotype","Prospective Study","Cohort Study","2026-05-07",{"date":630,"type":43},"2026-05-13",{"date":632,"type":21},"2026-05-01",{"date":634,"type":21},"2032-04-01",{"name":636,"class":85},"Zhujiang Hospital",{"id":638,"slug":4,"hasResults":11,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":644,"targetDuration":646,"studyType":61,"phases":4,"briefSummary":647,"conditions":648,"keywords":662,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":51},"100636568","NCT07567378","CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry","Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort","CARTIZ","Inclusion Criteria:\n\n* 1\\. Age ≥18 years at the time of informed consent. 2. Currently receiving tirzepatide under an independent clinical indication (type 2 diabetes, insulin resistance, obesity with or without associated metabolic disease, renal protection, metabolic hypertension, or associated off-label metabolic use) prescribed by the treating physician independently of the registry.\n\n  3\\. Presence of at least one objectively documented musculoskeletal manifestation - current or historical - defined as any of: (i) inflammatory arthralgia affecting one or more joints with clinical, imaging, or serological support; (ii) CASPAR-positive psoriatic arthritis; (iii) radiographically documented knee osteoarthritis; (iv) enthesitis on physical examination or ultrasound; (v) documented inflammatory arthropathy of the spine or peripheral joints with a specialist diagnosis.\n\n  4\\. For the retrospective-prospective component: availability of clinical documentation of articular state prior to tirzepatide initiation in the patient's medical record. Documentation may include physical examination notes, imaging, laboratory values, or specialist consultation notes.\n\n  5\\. Signed informed consent for registry enrolment, longitudinal serum biobanking, HLA typing at INCMNSZ, quantitative knee MRI with T2 mapping at Ci3M UAM-Iztapalapa at Week 0 and Week 52, non-contrast cardiac CT at INCar at Week 0 and Week 52, multi-frequency bioelectrical impedance analysis at Universidad La Salle México at six timepoints, and (where applicable) medical record review. Each attestation is consented modularly within a single document.\n\n  6\\. Clinical plan to continue tirzepatide for at least 52 weeks from registry Week 0, based on the treating physician's evaluation of current clinical indication. Discontinuation during follow-up is captured as an outcome variable and does not remove the patient from the registry.\n\n  7\\. Capacity to attend scheduled follow-up visits and to undergo bilateral knee MRI at Ci3M (without severe claustrophobia requiring sedation, without absolute contraindication to MRI - see Exclusion 6) and non-contrast cardiac CT at INCar (without uncontrolled arrhythmia precluding ECG-gated imaging of diagnostic quality).\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional criteria applied at the time of subcohort enrolment:\n\n8s. Scheduled clinically indicated cardiac surgery at the Instituto Nacional de Cardiología Ignacio Chávez (coronary artery bypass grafting, valve replacement, or combined procedures) during registry follow-up.\n\n9s. Specific additional informed consent for intraoperative collection of epicardial adipose tissue fragments.\n\nExclusion Criteria:\n\n* 1\\. Initiation or modification of a biologic disease-modifying antirheumatic drug (biologic DMARD) or JAK inhibitor within the 12 weeks prior to Week 0, or clinically anticipated initiation or modification during the first 12 weeks of follow-up. Washout may permit re-screening.\n\n  2\\. Major joint surgery within the 3 months prior to Week 0, or planned major joint surgery within the 12 months following Week 0, involving any joint scheduled for evaluation in the registry.\n\n  3\\. Intra-articular corticosteroid or hyaluronic acid injection within the 6 weeks prior to baseline biospecimen collection in any joint. Patients beyond the 6-week washout are eligible.\n\n  4\\. Active malignancy, with the exception of adequately treated non-melanoma skin carcinoma. History of malignancy in remission ≥5 years is permitted at the discretion of the treating investigator.\n\n  5\\. Current pregnancy, lactation, or planned pregnancy within the 12-month observation period.\n\n  6\\. Absolute contraindication to MRI, including non-MRI-compatible cardiac pacemaker or implanted defibrillator, ferromagnetic intracranial vascular clips, non-documented non-MRI-compatible cochlear implants, or other contraindication per the local MRI safety protocol.\n\n  7\\. Systemic rheumatologic disease other than psoriatic arthritis or osteoarthritis requiring active immunomodulation, specifically: seropositive rheumatoid arthritis on biologic therapy, active systemic lupus erythematosus on immunomodulation, active vasculitis on immunosuppression, or other systemic disease whose treatment confounds the inflammatory axis the registry is designed to characterize.\n\n  8\\. Inability to provide informed consent (cognitive impairment, language barrier not resolvable with site interpreter, or other incapacity to understand the protocol), or anticipated inability to complete the 52-week follow-up.\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional exclusions:\n\n9s. Prior major cardiac surgery resulting in extensive pericardial adhesions that preclude safe intraoperative EAT fragment collection, as assessed by the operating cardiac surgeon.\n\n10s. Emergency cardiac surgery precluding the specific informed consent process.",{"count":645,"type":21},30,"52 Weeks","CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1\u002FGIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, or supply tirzepatide, and does not dictate dose, route, or duration. All pharmacological exposure decisions are made by the treating physician independently of study participation. The registry is operationalized through a four-institute architecture integrating three Mexican National Institutes of Health and one national imaging laboratory. Core 1 (Knee Cartilage Imaging, Ci3M UAM-Iztapalapa) performs bilateral 3T MRI with quantitative T2 mapping at Week 0 and Week 52. Core 2 (Cardiac Imaging, Instituto Nacional de Cardiología Ignacio Chávez) performs non-contrast cardiac computed tomography for radiomic phenotyping of epicardial adipose tissue at Week 0 and Week 52 under cardiovascular Co-Principal Investigator Dr. Erick Alexánderson Rosas. Core 3 (HLA Typing, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Transplant Department) performs Class I and Class II HLA typing by PCR-SSO Reverse Luminex. Core 4 (Body Composition, Universidad La Salle México) performs multi-frequency bioelectrical impedance analysis (seca mBCA) at six longitudinal timepoints capturing visceral adipose tissue trajectory, phase-angle trajectory, appendicular skeletal muscle mass, and hydration ratios at zero marginal cost. The registry enrolls n=30 patients across three clinical sites with identical protocol (IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, and a private practice site in Mexico City), generating 60 evaluable knees and 30 paired cardiac CT studies. The primary co-endpoints address a mechanistic question no other tirzepatide study is positioned to answer: whether the articular response to tirzepatide in inflammatory arthropathy precedes and mechanistically precedes weight loss, through formal mediation analysis of Week-4 ACR20 response via high-sensitivity C-reactive protein, SERPINB2, and dipeptidyl peptidase-4 activity, restricted to the Mechanistic Analysis Set of patients with tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI \\\u003C1.0 kg\u002Fm² through Week 4. A prespecified Surgical Tissue Subcohort is declared at initial registration to establish public scientific priority on direct human epicardial adipose tissue transcriptomic characterization under dual GIP\u002FGLP-1 receptor agonism. Subcohort participants who undergo clinically indicated cardiac surgery at INCar during follow-up (coronary artery bypass grafting, valve replacement, or combined procedures) are invited to provide specific additional informed consent for collection of epicardial adipose tissue fragments routinely excised during operative access and otherwise discarded as surgical waste. Operational launch is contingent on separate INCar tissue-specific approvals and will proceed via PRS record amendment when ready",[649,650,651,652,590,653,654,29,655,656,657,658,659,660,661],"Psoriatic Arthritis","Osteoarthitis","Knee","Diabetes (DM)","Obesity (Disorder)","Insulin Resistance Syndrome","Heart Failure","Preserved Ejection Fraction","Coronary Artery Disease","Atrial Fibrillation (AF)","Non Alcholic Fatty Liver Disease","Sarcopenia","Pericardium",[663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684],"Tirzepatide","Dual GIP\u002FGLP-1 receptor agonist","Multi-nutrient-stimulated hormones","Psoriatic arthritis","Inflammatory arthropathy","ACR20","Cartilage T2 mapping","Quantitative knee MRI","Epicardial adipose tissue","Cardiac CT radiomics","Fat Attenuation Index","HLA typing","Visceral adipose tissue","Phase angle","seca mBCA","Bioelectrical impedance analysis","Mediation analysis","Weight-independent effect","Off-label exposure","Mexican registry","Epicardial adipose transcriptomics","Single-nucleus RNA sequencing",{"date":686,"type":43},"2026-05-12",{"date":688,"type":21},"2026-05",{"date":690,"type":21},"2029-05",{"name":692,"class":85},"JULIO GRANADOS MONTIEL",{"id":694,"slug":4,"hasResults":11,"nctId":695,"briefTitle":696,"officialTitle":696,"acronym":697,"eligibilityCriteria":698,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":699,"targetDuration":4,"studyType":22,"phases":701,"briefSummary":703,"conditions":704,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":705,"startDateStruct":707,"completionDateStruct":709,"leadSponsor":711,"locationsCount":51},"100513983","NCT05972564","The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","SADIE2","Inclusion Criteria:\n\n1. Age 18+ years old\n2. Metabolic syndrome as defined by 3 or more of 5 criteria:\n\n   1. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmg Hg or treatment with anti-hypertensive medications for minimum of 1 month\n   2. Triglycerides ≥ 150 mg\u002FdL or treatment with a triglyceride-targeted medication (fenofibrate, gemfibrozil, niacin, high dose omega-3 fatty acids)\n   3. High-density lipoprotein (HDL) \\\u003C 40 mg\u002FdL in males or \\\u003C 50 mg\u002FdL in females\n   4. Fasting blood glucose ≥ 100mg\u002FdL or treatment with glucose-lowering medications\n   5. Waist circumference ≥ 102 cm in males or ≥ 88cm in females\n3. BMI ≥ 35 kg\u002FM2\n4. Scheduled gastric bypass or gastric sleeve in approximately 90 days (range 90-270 days)\n5. The ability to provide informed consent\n\n   Exclusion Criteria:\n6. Type 1 diabetes.\n7. Poorly controlled type 2 diabetes as defined by HbA1c ≥ 9%.\n8. Use of anti-diabetic medications other than stable dose of metformin or a sulfonylurea in the last 1 month.\n9. Treatment with a glucagon-like peptide-1 receptor agonist or co-agonist in the last 3 months.\n10. Treatment with an SGLT2 inhibitor in the last 3 months.\n11. Pregnancy or breast-feeding. Women of child-bearing potential will be required to have undergone surgical sterilization or to be using an intra-uterine device, hormonal contraceptive, or barrier methods of birth control.\n12. Cardiovascular disease such as myocardial infarction within six months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (left ventricular hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, -second- or third-degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy\n13. Presence of implanted cardiac defibrillator or pacemaker\n14. History of serious neurologic disease such as cerebral hemorrhage, stroke, or transient ischemic attack\n15. History of pancreatitis or pancreatic surgery\n16. History or presence of immunological or hematological disorders\n17. Clinically significant gastrointestinal impairment that could interfere with drug absorption\n18. History of advanced liver disease with cirrhosis\n19. Individuals with an eGFR\\\u003C45 mL\u002Fmin\u002F1.73 m2, where eGFR is determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine is expressed in mg\u002FdL and age in years: eGFR (mL\u002Fmin\u002F1.73m2)=186 • Scr-1.154 • age-0.203 • (0.742 if female)\n20. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)\n21. Treatment with anticoagulants\n22. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult\n23. History of alcohol abuse (\\>14 per week for men and \\>7 per week for women) or illicit drug use\n24. Treatment with any investigational drug in the one month preceding the study\n25. Previous randomization in this trial\n26. Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study\n27. Inability to comply with the protocol in the opinion of the principal investigator, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study\n\n    Criteria Related to Known Adverse Effects of Drug:\n28. Uncircumcised men or men with history of balanitis\n29. History of urinary incontinence\n30. History of recurrent (\\>3) episodes of vulvovaginitis per year, or severe symptoms\n31. History of Fournier's gangrene\n32. History of recurrent (≥3) UTIs per year or pyelonephritis\n33. History of symptomatic hypotension or conditions predisposing to volume depletion\n34. Known peripheral vascular disease, neuropathy, history of foot ulcers or lower limb amputations\n35. Treatment with loop diuretics furosemide, torsemide, bumetanide, ethacrynic acid\n36. Known or suspected allergy to trial medications, excipients, or related products\n37. Contraindications to study medications, worded specifically as stated in the product's prescribing information",{"count":700,"type":21},74,[702,24],"PHASE1","Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathways in humans is key to future therapeutic interventions. This trial will determine both the anti-inflammatory potential of the SGLT2 inhibitor empagliflozin, and the contribution of adipose inflammation to surrogate measures of cardiovascular disease in a randomized controlled trial of obese patients.",[433,29],{"date":706,"type":43},"2026-05-11",{"date":708,"type":43},"2023-09-06",{"date":710,"type":21},"2026-12-30",{"name":712,"class":85},"Vanderbilt University Medical Center",{"id":714,"slug":4,"hasResults":11,"nctId":715,"briefTitle":716,"officialTitle":717,"acronym":718,"eligibilityCriteria":719,"healthyVolunteers":106,"sex":16,"minAge":720,"maxAge":721,"enrollmentInfo":722,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":724,"conditions":725,"keywords":726,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":730,"startDateStruct":731,"completionDateStruct":733,"leadSponsor":735,"locationsCount":51},"100139372","NCT01084967","Genetics of Obesity in Chinese Youngs","Study of Clinical Characteristics and Genetic Susceptibility in Chinese Obese Youngs","GOCY","Inclusion Criteria:\n\n* body mass index (BMI)≥ 30kg\u002Fm2\n* predominantly east China to minimize population stratification\n* willing and able to provide informed consent\n\nExclusion Criteria:\n\n* pregnancy\u002Flactation\n* Cushing syndrome\n* Hypothyroidism\n* obesity caused by pituitary and hypothalamic lesions\n* drug related obesity\n* history of major psychiatric illness","14 Years","30 Years",{"count":723,"type":21},8000,"The purpose of this study is to explore the pathogenesis and genetic susceptibility of obese subjects,providing a convincing argument for further treatment of obesity and metabolic syndrome.",[433,29],[727,209,728,729],"obesity","genetic risk markers","copy number variation",{"date":686,"type":43},{"date":732,"type":4},"2009-03",{"date":734,"type":21},"2030-04",{"name":736,"class":85},"Shanghai Jiao Tong University School of Medicine",{"id":738,"slug":4,"hasResults":11,"nctId":739,"briefTitle":740,"officialTitle":740,"acronym":741,"eligibilityCriteria":742,"healthyVolunteers":106,"sex":16,"minAge":452,"maxAge":508,"enrollmentInfo":743,"targetDuration":4,"studyType":22,"phases":744,"briefSummary":745,"conditions":746,"keywords":749,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":753,"lastUpdatePostDateStruct":754,"startDateStruct":756,"completionDateStruct":758,"leadSponsor":760,"locationsCount":51},"100362068","NCT03994367","Animal and Plant Proteins and Glucose Metabolism","HP","Inclusion Criteria:\n\n* age: ≥21 and ≤70 years;\n* BMI: \\>24.5 and \\\u003C32.5 kg\u002Fm2;\n* habitual protein intake \\\u003C0.9 g\u002Fkg\u002Fday (assessed on 2 weekdays and 2 weekend days by using the HealthWatch 360 app); and\n* weight stable (i.e., ≤3% change) and untrained (≤150 min of structured exercise\u002Fweek) for at least 2 months before entering the study.\n\nExclusion Criteria:\n\n* prediabetes or type 2 diabetes;\n* evidence of chronic kidney disease by medical history or laboratory tests (glomerular filtration rate \\\u003C60 ml\u002Fmin\u002F1.73 m2 or an albumin to creatinine ratio in urine ≥30 mg\u002Fg);\n* vegetarians or vegans;\n* intolerance or allergies to ingredients in the metabolic meal or intervention diet;\n* take dietary supplements (e.g., pre- and probiotics, fiber, fish oil) or medications known to affect our study outcomes;\n* received antibiotic or antifungal treatment (which affect the microbiome and therefore microbial metabolite production) 2 months before entering the study;\n* consume tobacco products or excessive alcohol (women: \\>14 drinks\u002Fweek; men: \\>21 drinks\u002Fweek);\n* evidence of significant organ system dysfunction or diseases (e.g., cirrhosis), and\n* unwilling or unable to provide informed consent.",{"count":20,"type":21},[110],"The goal of this proposal is to determine the effect of a high protein diet in which the increase in protein intake is derived from different sources (animal vs plant and protein-rich whole foods vs protein isolates) on: i) liver and muscle insulin sensitivity; ii) the metabolic response to a meal, and iii) 24-h plasma concentration profiles of glucose, glucoregulatory hormones, and protein-derived metabolites purported to cause metabolic dysfunction.",[29,747,748],"Metabolic Syndrome, Protection Against","Glucose Metabolism Disorders",[750,751,752],"High Protein","Metabolism","Diet","2026-05-05",{"date":755,"type":43},"2026-05-08",{"date":757,"type":43},"2019-07-12",{"date":759,"type":21},"2028-04-25",{"name":761,"class":85},"University of Missouri-Columbia",""]